These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 30106653)
21. Balancing Safety and Innovation for Cell-Based Regenerative Medicine. Marks P; Gottlieb S N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023 [No Abstract] [Full Text] [Related]
22. Study: Business Booms for Unlicensed and Unproven Stem Cell Treatments. Rubin R JAMA; 2022 Feb; 327(5):414-415. PubMed ID: 35019946 [No Abstract] [Full Text] [Related]
23. The implications of "advanced therapies" regulation. Sethe SC Rejuvenation Res; 2010; 13(2-3):327-8. PubMed ID: 20462386 [TBL] [Abstract][Full Text] [Related]
25. Evaluating the FDA regenerative medicine framework: opportunities for stakeholders. Richardson E; Akkas F; Master Z Regen Med; 2020 Jul; 15(7):1825-1832. PubMed ID: 32815780 [No Abstract] [Full Text] [Related]
26. 21st Century Cures Act and similar policy efforts: at what cost? Zuckerman DM; Jury NJ; Silcox CE BMJ; 2015 Nov; 351():h6122. PubMed ID: 26597099 [No Abstract] [Full Text] [Related]
27. FDA regulation of stem-cell-based therapies. Halme DG; Kessler DA N Engl J Med; 2006 Oct; 355(16):1730-5. PubMed ID: 17050899 [No Abstract] [Full Text] [Related]
28. Can we assure quality without stifling innovation? Miller L Stem Cells Dev; 2014 Dec; 23 Suppl 1(Suppl 1):66-7. PubMed ID: 25457966 [TBL] [Abstract][Full Text] [Related]
30. Stamina therapies: Let the record stand. Bianco P; Cattaneo E; De Luca M; Pani L Nature; 2014 Feb; 506(7489):434. PubMed ID: 24572414 [No Abstract] [Full Text] [Related]
31. Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments? Matthews K; Kunisetty B; Sprung K Stem Cells Dev; 2018 Nov; 27(21):1463-1465. PubMed ID: 30122128 [TBL] [Abstract][Full Text] [Related]
32. Stem cell research and policy in India: current scenario and future perspective. Sharma A J Stem Cells; 2009; 4(2):133-40. PubMed ID: 20232598 [TBL] [Abstract][Full Text] [Related]
33. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Knoepfler PS Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841 [TBL] [Abstract][Full Text] [Related]
34. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics. Smith DS Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924 [No Abstract] [Full Text] [Related]
35. Unproven but Profitable: The Boom in US Stem Cell Clinics. Rubin R JAMA; 2018 Oct; 320(14):1421-1423. PubMed ID: 30326510 [No Abstract] [Full Text] [Related]
37. Off-Label Marketing's Audiences: The 21 Halabi SF Am J Law Med; 2018 May; 44(2-3):181-196. PubMed ID: 30106659 [No Abstract] [Full Text] [Related]
38. Expansion of the Priority Review Voucher Program Under the 21 Sinha MS; Jain N; Hwang T; Kesselheim AS Am J Law Med; 2018 May; 44(2-3):329-341. PubMed ID: 30106661 [No Abstract] [Full Text] [Related]
39. Unproven stem cell-based interventions and achieving a compromise policy among the multiple stakeholders. Matthews KR; Iltis AS BMC Med Ethics; 2015 Nov; 16(1):75. PubMed ID: 26537611 [TBL] [Abstract][Full Text] [Related]
40. STER science and cardiothoracic surgery: an Asian perspective. Chiu RC Asian Cardiovasc Thorac Ann; 2008 Oct; 16(5):351-2. PubMed ID: 18812339 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]